A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Abstract Background Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient treatment for acute leukemia. The primary objective of this phase I single center open label study was to determine the maximum tolerated dose (M...

Full description

Bibliographic Details
Main Authors: Fabian Lang, Lydia Wunderle, Susanne Badura, Eberhard Schleyer, Monika Brüggemann, Hubert Serve, Susanne Schnittger, Nicola Gökbuget, Heike Pfeifer, Sebastian Wagner, Kevin Ashelford, Gesine Bug, Oliver G. Ottmann
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Pharmacology and Toxicology
Subjects:
Refractory ALL
Refractory AML
PI3K/mTor inhibition
BEZ235
Phase I clinical trial
Online Access:http://link.springer.com/article/10.1186/s40360-020-00446-x

Internet

http://link.springer.com/article/10.1186/s40360-020-00446-x

Similar Items